NHLBI

Driven by personal loss, a graduate student and his mentors unveil the mysteries of CFTR mutations, seeking to unlock new treatments for cystic fibrosis patients who currently resist available drugs. Read More

Led by Neil Osheroff, Vanderbilt researchers are the first to undertake a systematic analysis of the mechanism of action of geoptidacin. Gepotidacin is poised to become the first new class of antibacterials to be approved for use in humans in decades. Read More